BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Herring WJ, Connor KM, Snyder E, Snavely DB, Zhang Y, Hutzelmann J, Matzura-Wolfe D, Benca RM, Krystal AD, Walsh JK, Lines C, Roth T, Michelson D. Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials. J Clin Sleep Med 2016;12:1215-25. [PMID: 27397664 DOI: 10.5664/jcsm.6116] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Dujardin S, Pijpers A, Pevernagie D. Prescription Drugs Used in Insomnia. Sleep Med Clin 2020;15:133-45. [PMID: 32386689 DOI: 10.1016/j.jsmc.2020.02.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
2 Izuhara M, Miura S, Otsuki K, Nagahama M, Hayashida M, Hashioka S, Asou H, Kitagaki H, Inagaki M. Magnetic Resonance Spectroscopy in the Ventral Tegmental Area Distinguishes Responders to Suvorexant Prior to Treatment: A 4-Week Prospective Cohort Study. Front Psychiatry 2021;12:714376. [PMID: 34497544 DOI: 10.3389/fpsyt.2021.714376] [Reference Citation Analysis]
3 Dunn KE, Huhn AS, Bergeria CL, Gipson CD, Weerts EM. Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence. J Pharmacol Exp Ther 2019;371:422-52. [PMID: 31391211 DOI: 10.1124/jpet.119.258004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
4 Jacobson LH, Hoyer D, de Lecea L. Hypocretins (orexins): The ultimate translational neuropeptides. J Intern Med 2022. [PMID: 35043499 DOI: 10.1111/joim.13406] [Reference Citation Analysis]
5 Dujardin S, Pijpers A, Pevernagie D. Prescription Drugs Used in Insomnia. Sleep Medicine Clinics 2018;13:169-82. [DOI: 10.1016/j.jsmc.2018.03.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
6 Neylan TC, Richards A, Metzler TJ, Ruoff LM, Varbel J, O'Donovan A, Sivasubramanian M, Motraghi T, Hlavin J, Batki SL, Inslicht SS, Samuelson K, Morairty SR, Kilduff TS. Acute cognitive effects of the hypocretin receptor antagonist almorexant relative to zolpidem and placebo: a randomized clinical trial. Sleep 2020;43:zsaa080. [PMID: 32303763 DOI: 10.1093/sleep/zsaa080] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
7 Rosenberg R, Murphy P, Zammit G, Mayleben D, Kumar D, Dhadda S, Filippov G, LoPresti A, Moline M. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial. JAMA Netw Open 2019;2:e1918254. [PMID: 31880796 DOI: 10.1001/jamanetworkopen.2019.18254] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 15.3] [Reference Citation Analysis]
8 Hoyer D, Allen A, Jacobson LH. Hypnotics with novel modes of action. Br J Clin Pharmacol 2020;86:244-9. [PMID: 31756268 DOI: 10.1111/bcp.14180] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
9 van der Ark PD, Golor G, van Nueten L, Nandy P, de Boer P. Multiple daytime administration of the selective orexin-2 receptor antagonist JNJ-42847922 induces somnolence in healthy subjects without residual central effects. J Psychopharmacol 2018;32:1330-40. [DOI: 10.1177/0269881118791521] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
10 Yoshikawa F, Shigiyama F, Ando Y, Miyagi M, Uchino H, Hirose T, Kumashiro N. Chronotherapeutic efficacy of suvorexant on sleep quality and metabolic parameters in patients with type 2 diabetes and insomnia. Diabetes Res Clin Pract 2020;169:108412. [PMID: 32911037 DOI: 10.1016/j.diabres.2020.108412] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Herring WJ, Connor KM, Snyder E, Snavely DB, Morin CM, Lines C, Michelson D. Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: analysis of pooled phase 3 data. Sleep Medicine 2019;56:219-23. [DOI: 10.1016/j.sleep.2018.09.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
12 Svetnik V, Snyder ES, Tao P, Scammell TE, Roth T, Lines C, Herring WJ. Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake Bouts. Sleep 2018;41. [DOI: 10.1093/sleep/zsx178] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
13 Krystal AD, Prather AA. Sleep Pharmacogenetics: The Promise of Precision Medicine. Sleep Med Clin 2019;14:317-31. [PMID: 31375201 DOI: 10.1016/j.jsmc.2019.05.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
14 Sieminski M, Szypenbejl J, Partinen E. Orexins, Sleep, and Blood Pressure. Curr Hypertens Rep. 2018;20:79. [PMID: 29992504 DOI: 10.1007/s11906-018-0879-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
15 Han Y, Yuan K, Zheng Y, Lu L. Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders. Neurosci Bull 2020;36:432-48. [PMID: 31782044 DOI: 10.1007/s12264-019-00447-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
16 Takeuchi Y, Sano H, Asai Y, Miyazaki M, Iwakura M, Maeda Y. Real-world evidence of the safety and efficacy profile of suvorexant in elderly patients with insomnia: a sub-analysis of the post-marketing drug-use results survey in Japan. Current Medical Research and Opinion 2020;36:465-71. [DOI: 10.1080/03007995.2019.1700361] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Yee KL, Mccrea J, Panebianco D, Liu W, Lewis N, Cabalu T, Ramael S, Wrishko RE. Safety, Tolerability, and Pharmacokinetics of Suvorexant: A Randomized Rising-Dose Trial in Healthy Men. Clin Drug Investig 2018;38:631-8. [DOI: 10.1007/s40261-018-0650-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
18 Roth T, Rosenberg R, Morin CM, Yardley J, Pinner K, Perdomo C, Atkins N, Pappadopulos E, Malhotra M, Moline M. Impact of lemborexant treatment on insomnia severity: analyses from a 12-month study of adults with insomnia disorder. Sleep Medicine 2022. [DOI: 10.1016/j.sleep.2022.01.024] [Reference Citation Analysis]
19 Burfeind KG, Yadav V, Marks DL. Hypothalamic Dysfunction and Multiple Sclerosis: Implications for Fatigue and Weight Dysregulation. Curr Neurol Neurosci Rep 2016;16:98. [PMID: 27662896 DOI: 10.1007/s11910-016-0700-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
20 Voysey ZJ, Barker RA, Lazar AS. The Treatment of Sleep Dysfunction in Neurodegenerative Disorders. Neurotherapeutics 2021;18:202-16. [PMID: 33179197 DOI: 10.1007/s13311-020-00959-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
21 Uslaner JM, Herring WJ, Coleman PJ. The Discovery of Suvorexant: Lessons Learned That Can Be Applied to Other CNS Drug Development Efforts. ACS Pharmacol Transl Sci 2020;3:161-8. [PMID: 32259095 DOI: 10.1021/acsptsci.9b00110] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Hamidovic A. Dual Orexin Receptor Antagonists (DORAs) as an Adjunct Treatment for Smoking Cessation. CNS Drugs 2022. [PMID: 35451800 DOI: 10.1007/s40263-022-00918-0] [Reference Citation Analysis]
23 Yakupov EZ, Artemieva DV, Troshina YV. [Multimodality of clinical effects of orexin]. Zh Nevrol Psikhiatr Im S S Korsakova 2018;118:114-9. [PMID: 30698570 DOI: 10.17116/jnevro2018118121114] [Reference Citation Analysis]
24 Herring WJ, Ceesay P, Snyder E, Bliwise D, Budd K, Hutzelmann J, Stevens J, Lines C, Michelson D. Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial. Alzheimers Dement 2020;16:541-51. [PMID: 31944580 DOI: 10.1002/alz.12035] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 14.0] [Reference Citation Analysis]
25 Rosenberg R, Citrome L, Drake CL. Advances in the Treatment of Chronic Insomnia: A Narrative Review of New Nonpharmacologic and Pharmacologic Therapies. Neuropsychiatr Dis Treat 2021;17:2549-66. [PMID: 34393484 DOI: 10.2147/NDT.S297504] [Reference Citation Analysis]
26 Herring WJ, Roth T, Krystal AD, Michelson D. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications. J Sleep Res 2018;28. [DOI: 10.1111/jsr.12782] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
27 Hoyer D, Jacobson LH. Orexin Receptor Antagonists. Curr Sleep Medicine Rep 2017;3:342-53. [DOI: 10.1007/s40675-017-0099-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
28 Roehrs T, Withrow D, Koshorek G, Verkler J, Bazan L, Roth T. Sleep and pain in humans with fibromyalgia and comorbid insomnia: double-blind, crossover study of suvorexant 20 mg versus placebo. J Clin Sleep Med 2020;16:415-21. [PMID: 31992394 DOI: 10.5664/jcsm.8220] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Robertson I, Cheung A, Fan X. Insomnia in patients with schizophrenia: current understanding and treatment options. Prog Neuropsychopharmacol Biol Psychiatry 2019;92:235-42. [PMID: 30707986 DOI: 10.1016/j.pnpbp.2019.01.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
30 Sun H, Snyder E, Koch GG. Statistical planning in confirmatory clinical trials with multiple treatment groups, multiple visits, and multiple endpoints. J Biopharm Stat 2018;28:189-211. [PMID: 28992425 DOI: 10.1080/10543406.2017.1378664] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
31 Ng L, Cunnington D. Management of insomnia in primary care. Aust Prescr 2021;44:124-8. [PMID: 34421177 DOI: 10.18773/austprescr.2021.027] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Xu S, Cui Y, Shen J, Wang P. Suvorexant for the prevention of delirium: A meta-analysis. Medicine (Baltimore) 2020;99:e21043. [PMID: 32791676 DOI: 10.1097/MD.0000000000021043] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
33 Sano H, Asai Y, Miyazaki M, Iwakura M, Maeda Y, Hara M. Safety profile and clinical course of patients with insomnia administered suvorexant by initial treatment status in a post-marketing survey. Expert Opin Drug Saf 2019;18:1109-18. [PMID: 31478753 DOI: 10.1080/14740338.2019.1657091] [Reference Citation Analysis]